Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5202-5216

  Rudolph, Joachim ^a   Esler, William P ^a   O'Connor, Stephen ^a   Coish, Philip D G ^a   Wickens, Philip L ^a   Brands, Michael ^a   Bierer, Donald E ^a   Bloomquist, Brian T ^a   Bondar, Georgiy ^a   Chen, Libing ^a   Chuang, Chih Yuan ^a   Claus, Thomas H ^a   Fathi, Zahra ^a   Fu, Wenlang ^a   Khire, Uday R ^a   Kristie, James A ^a   Liu, Xiao Gao ^a   Lowe, Derek B ^a   McClure, Andrea C ^a   Michels, Martin ^a   Ortiz, Astrid A ^a   Ramsden, Philip D ^a   Schoenleber, Robert W ^a   Shelekhin, Tatiana E ^a   Vakalopoulos, Alexandras ^a   Tang, Weifeng ^a   Wang, Lei ^a   Yi, Lin ^a   Gardell, Stephen J ^a   Livingston, James N ^a   Sweet, Laurel J ^a   Bullock, William H ^a   more..

^a BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GHRELIN RECEPTOR BLOCKING AGENT; GLUCOSE; HORMONE RECEPTOR BLOCKING AGENT; INSULIN; PIPERIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FOOD INTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; NONHUMAN; OBESITY; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BINDING, COMPETITIVE; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS; EATING; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MICE; MICE, INBRED C57BL; OBESITY; QUINAZOLINONES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, GHRELIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; WEIGHT LOSS;

EID: 35348825010     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070071+     Document Type: Article

References (48)

1. Gan, D. Diabetes Atlas, 2nd ed.; International Diabetes Federation: Brussels, 2003.
2. Bailey, C. J. Drugs on the horizon for diabesity. Curr. Diabetes Rep. 2005, 5, 353-359.
3. van der Lely, A. J.; Tschop, M.; Heiman, M. L.; Ghigo, E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev. 2004, 25, 426-457.
4. Cummings, D. E.; Overduin, J.; Foster-Schubert, K. E. Roles for ghrelin in the regulation of appetite and body weight. Curr. Opin. Endocrinol. Diabetes 2005, 12, 72-79.
5. Popovic, V. Ghrelin. Curr. Opin. Endocrinol. Diabetes 2006, 13, 70-75.
6. Zhao, H.; Liu, G. Growth hormone secretagogue receptor antagonists as anti-obesity therapies? Still an open question. Curr. Opin. Drug Discovery Dev. 2006, 9, 509-515.
7. Volante, M.; Allia, E.; Gugliotta, P.; Funaro, A.; Broglio, F.; et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. 2002, 87, 1300-1308.
8. Adeghate, E.; Ponery, A. S. Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. J. Neuroendocrinal. 2002, 14, 555-560.
9. Wierup, N.; Svensson, H.; Mulder, H.; Sundler, F. The ghrelin cell: A novel developmentally regulated islet cell in the human pancreas. Regul. Pept. 2002, 107, 63-69.
10. Date, Y.; Nakazato, M.; Hashiguchi, S.; Dezaki, K.; Mondal, M. S.; et al. Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 2002, 51, 124-129.
11. Wierup, N.; Yang, S.; McEvilly, R. J.; Mulder, H.; Sundler, F. Ghrelin is expressed in a novel endocrine cell type in developing rat islets and inhibits insulin secretion from INS-1 (832/13) cells. J. Histochem. Cytochem. 2004, 52, 301-310.
12. 2+ signaling in beta-cells: Implication in the glycemic control in rodents. Diabetes 2004, 53, 3142-3151.
13. Kageyama, H.; Funahashi, H.; Hirayama, M.; Takenoya, F.; Kita, T.; et al. Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul. Pept. 2005, 126, 67-71.
14. Egido, E. M.; Rodriguez-Gallardo, J.; Silvestre, R. A.; Marco, J. Inhibitory effect of ghrelin on insulin and pancreatic somatostatin secretion. Eur. J. Endocrinol. 2002, 146, 241-244.
15. Doi, A.; Shono, T.; Nishi, M.; Furuta, H.; Sasaki, H.; et al. IA-2b, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 885-890.
16. Broglio, F.; Gottero, C.; Benso, A.; Prodam, F.; Destefanis, S.; et al. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J. Clin. Endocrinol. Metab. 2003, 88, 4268-4272.
17. Saad, M. F.; Bernaba, B.; Hwu, C. M.; Jinagouda, S.; Fahmi, S.; et al. Insulin regulates plasma ghrelin concentration. J. Clin. Endocrinol. Metab. 2002, 87, 3997-4000.
18. Cummings, D. E.; Purnell, J. Q.; Frayo, R. S.; Schmidova, K.; Wisse, B. E.; et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50, 1714-1719.
19. Tolle, V.; Bassant, M. H.; Zizzari, P.; Poindessous-Jazat, F.; Tomasetto, C.; et al. Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep-wake patterns in rats. Endocrinology 2002, 143, 1353-1361.
20. Toshinai, K.; Mondal, M. S.; Nakazato, M.; Date, Y.; Murakami, N.; et al. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun. 2001, 281, 1220-1225.
21. Sun, Y.; Wang, P.; Zheng, H.; Smith, R. G. Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 4679-4684.
22. Reimer, M. K.; Pacini, G.; Ahren, B. Dose-dependent inhibition by ghrelin of insulin secretion in the mouse. Endocrinology 2003, 144, 916-921.
23. Muller, A. F.; Janssen, J. A.; Hofland, L. J.; Lamberts, S. W.; Bidlingmaier, M.; et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J. Clin. Endocrinol. Metab. 2001, 86, 590-593.
24. Svensson, J.; Lonn, L.; Jansson, J. O.; Murphy, G.; Wyss, D.; et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J. Clin. Endocrinol. Metab. 1998, 83, 362-369.
25. Chapman, I. M.; Bach, M. A.; Van Cauter, E.; Farmer, M.; Krupa, D.; et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J. Clin. Endocrinol. Metab. 1996, 81, 4249-4257.
26. The synthesis of compounds 1 and 2 is described in the Supporting Information.
27. Fenton, G.; Newton, C. G.; Wyman, B. M.; Bagge, P.; Dron, D. I.; et al. Hypolipidemic 2-[4-(1,1-dimethylethyl)phenyl]-4H-3,1-benzoxazin-4-ones. Structure-activity relationships of a novel series of high-density lipoprotein elevators. J. Med. Chem. 1989, 32, 265-272.
28. Shcherbakova, I.; Balandrin, M. F.; Fox, J.; Ghatak, A.; Heaton, W. L.; et al. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett. 2005, 15, 1557-1560.
29. Herdemann, M.; Al-Mourabit, A.; Martin, M.-T.; Marazano, C. From a biogenetic scenario to a synthesis of the ABC ring of manzamine A. J. Org. Chem. 2002, 67, 1890-1897.
30. Frlan, R.; Kikelj, D. Recent progress in diaryl ether synthesis. Synthesis 2006, 2271-2285.
31. Daidone, G.; Plescia, S.; Raffa, D.; Schillaci, D.; Maggio, B.; et al. Synthesis, crystallographic studies and biological evaluation of some 2-substituted 3-indazolyl-4(3H)-quinazolinones and 3-indazolyl-4(3H)- benzotriazinones. Heterocycles 1996, 43, 2385-2396.
32. Salehi, P.; Dabiri, M.; Zolfigol, M. A.; Baghbanzadeh, M. A novel method for the one-pot three-component synthesis of 2,3-dihydro-quinazolin-4(1H)-ones. Synlett 2005, 1155-1157.
33. van Niel, M. B.; Collins, I.; Beer, M. S.; Broughton, H. B.; Cheng, S. K. F.; et al. Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(1-piperazinyl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles. J. Med. Chem. 1999, 42, 2087-2104.
34. http://www.acdlabs.com/products/phys_chem_lab/pka/.
35. Lipinski, C. A.; Hoffer, E. Compound properties and drug quality. Pract. Med. Chem. (2nd ed.) 2003, 341-349.
36. Holst et al. have demonstrated that recombinant GHS-R1a overexpressed in mammalian cells displays a high level of constitutive activity, the physiological relevance of which has not yet been fully understood. However, our observation that neutral antagonists promote weight loss and improve glucose homeostasis in rodents (vida infra) indicates that inverse agonism is not a prerequisite for efficacy in these models. Comparison of the effects of a strong inverse agonist with a neutral antagonist could provide further insight into the physiologic relevance of GHS-R1a constitutive activity. Holst, B.; Schwartz, T. W. Constitutive ghrelin receptor activity as a signaling set-point in appetite regulation. Trends Pharmacol. Sci. 2004, 25, 113-117.
37. http://www.daylight.com/dayhtml/doc/clogp/index.html.
38. Affinities for the homologous motilin receptor, the Serotonine receptors 5-HT2 a, b, and c, and the L type calcium channel receptor were > 1 μM for both compounds. Compound 43 was tested in a panel of overall 21 receptor assays and did not reveal any significant activities.
39. Carai, M. A. M.; Colombo, G.; Maccioni, P.; Gessa, G. L. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Preclinical and clinical data. CNS Drug Rev. 2006, 12, 91-99.
40. Cummings, D. E.; Foster-Schubert, K. E.; Overduin, J. Ghrelin and energy balance: Focus on current controversies. Curr. Drug Targets 2005, 6, 153-169.
41. Levin, B. E.; Dunn-Meynell, A. A.; Ricci, M. R.; Cummings, D. E. Abnormalities of leptin and ghrelin regulation in obesity-prone juvenile rats. Am. J. Physiol. 2003, 285, E949-E957.
42. The synthesis of compound 47 involved a slight variation of the sequence described in Scheme 1. Its preparation is described in the Supporting Information.
43. Serby, M. D.; Zhao, H.; Szczepankiewicz, B. G.; Kosogof, C.; Xin, Z.; et al. 2,4-Diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists. J. Med. Chem. 2006, 49, 2568-2578.
44. Kelder, J.; Grootenhuis, P. D. J.; Bayada, D. M.; Delbressine, L. P. C.; Ploemen, J.-P. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm. Res. 1999, 16, 1514-1519.
45. Ertl, P.; Rohde, B.; Selzer, P. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 2000, 43, 3714-3717.
46. Sun, Y.; Asnicar, M.; Saha, P. K.; Chan, L.; Smith, R. G. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006, 3, 379-386.
47. Esler, W. P.; Rudolph, J.; Claus, T. H.; Brands, M.; Tang, W.; et al. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology, in press.
48. Pan, C. Q.; Buxton, J. M.; Yung, S. L.; Tom, I.; Yang, L.; et al. Design of a long acting peptide functioning as both a glucagon-like peptide-1 receptor agonist and a glucagon receptor antagonist. J. Biol. Chem. 2006, 281, 12506-12515.